Literature DB >> 27287003

Use of S-100B, NSE, CRP and ESR to predict neurological outcomes in patients with return of spontaneous circulation and treated with hypothermia.

Seungwoon Choi1, Kyunam Park2, Seokyong Ryu1, Taekyung Kang1, Hyejin Kim1, Sukjin Cho1, Sungchan Oh1.   

Abstract

BACKGROUND: With the introduction of therapeutic hypothermia (TH), the prediction of neurological outcomes in cardiac arrest (CA) survivors is challenging. Early, accurate determination of prognosis by emergency physicians is important to avoid unnecessarily prolonged critical care with a likely poor neurological outcome.
METHODS: This prospective observational study included patients with non-traumatic CA and return of spontaneous circulation (ROSC) between March 2009 and May 2012 at a tertiary academic hospital. Unconscious patients with ROSC were treated with mild TH (32°C-34°C) for 24 hours. Blood samples were collected for S-100B, neuron-specific enolase (NSE), C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) at 0, 24 and 48 hours post-ROSC. Neurological outcomes were evaluated at hospital discharge and dichotomised as good (cerebral performance category (CPC) 1 or 2) or poor (CPC 3, 4 or 5).
RESULTS: Of the 119 patients (68.1% male, 53±15.6 years old) who underwent TH, 46 patients had a good outcome (38.9%). Poor neurological outcomes were predicted using receiver operating characteristic analyses at cut-off values of 0.12 g/L for S-100B at 24 hours post-ROSC (sensitivity, 95.0%; specificity, 75.6%; area under the curve (AUC) 0.916; 95% CI of AUC: 0.846 to 0.961), 31.03 ng/mL for NSE at 48 hours post-ROSC (sensitivity, 83.9%; specificity, 96.9%; AUC 0.929; 95% CI of AUC: 0.836 to 0.979) and 11.2 mg/dL for CRP at 48 hours post-ROSC (sensitivity, 69.4%; specificity, 75.0%; AUC 0.731; 95% CI of AUC: 0.617 to 0.827). ESR was not significant.
CONCLUSIONS: Among the biomarkers, S-100B at 24 hours and NSE at 48 hours post-ROSC were highly predictive of neurological outcomes in patients treated with TH after CA. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/

Entities:  

Keywords:  cardiac arrest; hypothermia; neurology

Mesh:

Substances:

Year:  2016        PMID: 27287003     DOI: 10.1136/emermed-2015-205423

Source DB:  PubMed          Journal:  Emerg Med J        ISSN: 1472-0205            Impact factor:   2.740


  5 in total

1.  Factors associated with fatal outcome in posterior reversible encephalopathy syndrome: a retrospective analysis of the Berlin PRES study.

Authors:  Eberhard Siebert; G Bohner; T Liebig; M Endres; T G Liman
Journal:  J Neurol       Date:  2016-11-04       Impact factor: 4.849

2.  Efficacy of Thiamine in the Treatment of Postcardiac Arrest Patients: A Randomized Controlled Study.

Authors:  Suntornwit Pradita-Ukrit; Veerapong Vattanavanit
Journal:  Crit Care Res Pract       Date:  2020-06-08

3.  Serum S100 Protein Is a Reliable Predictor of Brain Injury After Out-of-Hospital Cardiac Arrest: A Cohort Study.

Authors:  Martin Kleissner; Marek Sramko; Jan Kohoutek; Josef Kautzner; Jiri Kettner
Journal:  Front Cardiovasc Med       Date:  2021-02-09

4.  Quantitative pupillometry and neuron-specific enolase independently predict return of spontaneous circulation following cardiogenic out-of-hospital cardiac arrest: a prospective pilot study.

Authors:  Shoji Yokobori; Kevin K K Wang; Zhihui Yang; Tian Zhu; Joseph A Tyndall; Stefania Mondello; Yasushi Shibata; Naoki Tominaga; Takahiro Kanaya; Toru Takiguchi; Yutaka Igarashi; Jun Hagiwara; Ryuta Nakae; Hidetaka Onda; Tomohiko Masuno; Akira Fuse; Hiroyuki Yokota
Journal:  Sci Rep       Date:  2018-10-29       Impact factor: 4.379

5.  Growth differentiation factor 15 and early prognosis after out-of-hospital cardiac arrest.

Authors:  Ferran Rueda; Germán Cediel; Cosme García-García; Júlia Aranyó; Marta González-Lopera; M Cruz Aranda Nevado; Judith Serra Gregori; Teresa Oliveras; Carlos Labata; Marc Ferrer; Nabil El Ouaddi; Antoni Bayés-Genís
Journal:  Ann Intensive Care       Date:  2019-10-17       Impact factor: 6.925

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.